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INTRODUCTION
Diagnosis of extremely well differentiated papillary thyroid 
carcinoma (EWD-PTC) is controversial, and has not been 
clearly defined. Similar to EWD-PTC, diagnosis of follicular 
variant papillary thyroid carcinoma (FVPTC) is also contro-
versial. The diagnosis is not so problematic when its nuclear 
features are typical of papillary thyroid carcinoma (PTC), how-
ever, its interpretation becomes a diagnostic dilemma when 
the nuclear features are not as typical.1,2 Diagnosis of well dif-
ferentiated tumors of uncertain malignant potential (WDT-
Extremely Well-Differentiated Papillary Thyroid  
Carcinoma Resembling Adenomatous Hyperplasia 
Can Metastasize to the Skull: A Case Report 
Ju Yeon Pyo1, Jisup Kim1, Sung-eun Choi1, Eunah Shin2, Seok-Woo Yang3,  
Cheong Soo Park4, Seok-Mo Kim4, and SoonWon Hong1
1Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul;
2Department of Pathology, CHA Gangnam Hospital, CHA University Medical School, Seoul;
3Department of Pathology, Yonsei MokGu Clinic, Seosan;
4Thyroid Cancer Center, Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
We describe herein histologic, immunohistochemical, and molecular findings and clinical manifestations of a rare case of an ex-
tremely well differentiated papillary thyroid carcinoma (EWD-PTC). Similarly, it is also difficult to diagnose follicular variant pap-
illary thyroid carcinoma (FVPTC), whose diagnosis is still met with controversy. A recently reported entity of well-differentiated 
tumor of uncertain malignant potential (WDT-UMP) is added to the diagnostic spectrum harboring EWD-PTC and FVPTC. We re-
port this case, because EWD-PTC is different from FVPTC in its papillary architecture, and also from WDT-UMP in its recurrence 
and metastatic pattern. These morphologically deceptive entities harbored diagnostic difficulties in the past because the diagno-
sis depended solely on histology. However, they are now diagnosed with more certainty by virtue of immunohistochemical and mo-
lecular studies. We experienced a case of EWD-PTC, which had been diagnosed as adenomatous hyperplasia 20 years ago and 
manifested recurrence with lymph node (LN) metastasis 7 years later. After another 7 years of follow-up, a new thyroid lesion had 
developed, diagnosed as FVPTC, with LN metastasis of EWD-PTC. One year later, the patient developed metastatic FVPTC in the 
skull. Immunohistochemically, the EWD-PTC was focally positive for CK19, negative for galectin-3, and focally negative for CD56. 
Molecular studies revealed BRAF-positivity and K-RAS negativity. The FVPTC in the left thyroid showed both BRAF and K-RAS 
negativity. In conclusion, EWD-PTC and FVPTC share similar histologic features, but they are different tumors with different mo-
lecular biologic and clinical manifestations. A large cohort of EWD-PTC should be included in further study.
Key Words:  CD56, immunohistochemistry; papillary thyroid carcinoma; follicular epithelial dysplasia; adenomatous hyperplasia; 
extremely well-differentiated; well-differentiated tumors of uncertain malignant potential
Case Report
pISSN: 0513-5796 · eISSN: 1976-2437
Received: October 5, 2015   Revised: October 28, 2015
Accepted: November 5, 2015
Corresponding author: Dr. SoonWon Hong, Department of Pathology, Gangnam 
Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gang-
nam-gu, Seoul 06273, Korea.
Tel: 82-2-2019-3540, Fax: 82-2-3463-2103, E-mail: soonwonh@yuhs.ac 
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2017
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2017 Jan;58(1):255-258
https://doi.org/10.3349/ymj.2017.58.1.255
256
EWD-PTC
https://doi.org/10.3349/ymj.2017.58.1.255
UMP) has been suggested in cases showing that nuclear fea-
tures are histologically inadequate for PTC and also clinical 
features inadequate for malignancy, thus avoiding overtreat-
ment.3,4 We herein report a case showing histologic features 
similar to WDT-UMP, but with clinically malignant behavior. 
Insight understanding of such a deceptive case will enable pa-
thologists to reach an accurate diagnosis and clinicians to de-
cide the most appropriate treatment plan.
CASE REPORT
A 25-year-old man presented with a large solid and colloid 
mass measuring 10×7 cm in the right thyroid, which was diag-
nosed as adenomatous hyperplasia. Seven years later, he pre-
sented with a 4 cm-sized, suddenly growing mass in the right 
side of the neck, and completion right total thyroidectomy with 
lymph node (LN) dissection was done. The specimen consist-
ed of 16 LNs with metastatic follicular thyroid lesions showing 
no definite nuclear features of PTC (Fig. 1A). Immunohisto-
chemistry for CK19 (DAKO, Glostrup, Denmark) and Galectin-3 
(NOVOCASTRA, Newcastle, UK) were done, and although 
their results were not supportive (Fig. 1B), the LN were diag-
nosed as metastatic PTC, considering the metastatic pattern. 
Radioactive iodine (RAI) therapy was not done because the 
left thyroid was preserved. Another seven years later, he de-
A
C
F
I
B
D E
G H
J K
Fig. 1. Neck lymph node (LN) shows metastatic extremely well differentiated papillary thyroid carcinoma (EWD-PTC) (A, H-E stain, ×12.5 and inset ×400) 
with focal positivity of CK19 (B, ×400) in the first metastatic lesion. The left thyroid shows follicular variant papillary thyroid carcinoma (FVPTC) without 
capsular (arrow) invasion (C, H-E stain, ×40 and inset ×400) with focal positivity of CK19 (D, ×40) and loss of CD56 (E, ×40) in second episode. The LN also 
shows metastatic EWD-PTC (F, H-E stain, ×12.5 and inset ×400) with focal positivity of CK19 (G, ×400) and CD56 (H, ×400) in the second metastatic lesion. 
The skull lesion shows metastatic FVPTC (I, H-E stain, ×100 and inset ×400) with focal positivity of CK19 (J, ×400) and CD56 (K, ×400).
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veloped a mass in the left thyroid, which was diagnosed as en-
capsulated FVPTC without capsular or vascular invasion (Fig. 
1C), and metastatic LNs displaying same histology as the sec-
ond presentation (Fig. 1F). Again, the FVPTC did not show typi-
cal nuclear features of PTC, and the immunohistochemistry 
results of CK19, Galectin-3, and p63 (NOVOCASTRA) were 
not supportive. However, immunohistochemistry for CD56 
(ZYMED, South San Francisco, CA, USA) revealed loss of ex-
pression in the follicular cells, rendering the diagnosis of FVPTC 
(Fig. 1D and E). Immunohistochemical profile of the metastatic 
PTC in the LNs was the same as that of FVPTC (Fig. 1G and H).5 
Preoperative thyroglobulin level was 321.85 ng/mL, which 
dropped to 185.82 ng/mL postoperatively (Table 1). The pa-
tient received RAI 150 mCi treatment, and the thyroglobulin 
level decreased to 49.0 ng/mL with thyroid stimulating hor-
mone (TSH) suppression. Six months later, due to radiologi-
cally suspicious metastatic lesion in the frontal bone and left 
5th rib with thyroglobulin level of 460.0 ng/mL, the patient un-
derwent surgical removal of the skull lesion, diagnosed as 
metastatic FVPTC (Fig. 1I, J, and K) and received additional 
RAI 200 mCi treatment. Afterwards, the patient received palli-
ative radiation on the skull and additional RAI 200 mCi treat-
ments. Presently, no remarkable change in the activity of ra-
dioiodine uptake is seen in the bone, and the thyroglobulin level 
is 0.7 ng/mL with TSH suppression; thus, the patient is consid-
ered to be in well-controlled status (Table 1). We performed 
immunohistochemistry for CD31 (DAKO) and PPAR-γ (CELL 
SIGNALING, Danvers, MA, USA) for detecting vascular inva-
sion of FVPTC, and molecular studies for BRAF and K-RAS in 
available specimen after the third presentation employing PNA 
clamping method (Panagene, Daejeon, Korea).6 When the 
FVPTC was thoroughly examined, no capsular invasion was 
identified, and no vascular invasion was seen on immunohis-
tochemistry. Both the FVPTC and the LN metastasis showed 
wild type of K-RAS. In BRAF study, only the LN metastasis showed 
mutation, but the FVPTC and bone metastasis did not (Table 2). 
DISCUSSION
Since the introduction of FVPTC, its diagnostic criteria have 
been established and settled over time, nevertheless, a wide 
spectrum of interobserver variability still exists even among 
thyroid experts,2 thus lowering diagnostic accuracy in cytology 
and intraoperative frozen sections.7,8 Adenomatous hyperpla-
sia showing nuclear features reminiscent, but not quite diag-
nostic, of PTC have been most troublesome, and they were 
generally passed as adenomatous hyperplasia, because cellu-
lar atypia to some degree, increase in size, and recurrence are 
all possible in adenomatous hyperplasia. With this diagnostic 
dilemma, many ancillary diagnostic tools have been impro-
vised to increase the diagnostic accuracy in FVPTC; immuno-
histochemistry for CK19, HBME1, and galectin-3 have been 
shown to be helpful in the diagnosis of PTC. However, the re-
sults have not been satisfactory. The loss of CD56 immunore-
activity in the follicular cells have been reported to be specific 
to PTC, and our experience indicates that the loss of CD56 im-
munoreactivity is relatively specific to conventional PTC as well 
as FVPTC.9 When our patient first presented with thyroid mass 
20 years ago, the concept of FVPTC had not yet been intro-
duced. Seven years later when the tumor metastasized to the 
LNs, the cytologic features were insufficient for the diagnosis 
of PTC. Moreover, the tumor showed negative immunohisto-
chemistry for CK19, HBME1, and galectin-3. The diagnosis of 
Table 1. Summary of Biochemical Data
T3 (ng/mL) Free T4 (ng/dL) TSH (μIU/mL) Thyroglobulin (ng/mL) Thyroglobulin Ab (IU/mL)
1 year prior to 3rd presentation NA NA 1.48 321.85 43.48
Status post-operation of 3rd presentation NA 2.36 2.12 185.85 86.34
Status post-first RAI treatment NA 1.06 2.38 49.03 103.26
4th Bone metastasis NA 0.17 80.59 >460.00 52.27
Status post-operation of 4th presentation NA 5.32 <0.025 4.2 79.8
Recent (after 5th RAI treatment, 
  cumulated dose=950 mci)
1.14 1.65 <0.025 0.7 24.0
TSH, thyroid stimulating hormone; Ab, antibody; NA, not available; RAI, radioactive iodine.
Table 2. Summary of Histopathologic Findings, Immunohistochemistry and Molecular Study
Histopathology CK19 Gal-3 CD56 PPAR-γ BRAF K-RAS
1st thyroid AH (initial) EWD-PTC NA NA NA NA NA NA
2nd LN Metastatic EWD-PTC Focal+ - NA NA NA NA
3rd thyroid FVPTC, encapsulated Focal+ - Focal+ - Wild Wild
3rd LN Metastatic EWD-PTC Focal+ - Focal+ - Mutation Wild
4th Skull Metastatic FVPTC Focal+ - Focal+ - Wild Fail
CK19, cytokeratin 19; Gal-3, galectin-3; PPAR-γ, peroxisome proliferator-actiated receptor-γ; AH, adenomatous hyperplasia; EWD-PTC, extremely well differenti-
ated papillary thyroid carcinoma; FVPTC, follicular variant papillary thyroid carcinoma; NA, not available.
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LN metastasis was solely based on the metastatic pattern of the 
tumor. Such cases present diagnostic dilemma, and clinical 
evidence of malignancy is even more difficult to find if follow-
up period is short. Many efforts have been spent for finding the 
most appropriate diagnosis for such cases, and resulted in the 
newly evolving diagnosis of thyroid tumors of uncertain ma-
lignant potential, reflecting the borderline clinical behavior. 
Recurrence or metastasis has not been found in such cases, 
although the longest follow-up period was 9 years. No molec-
ular biologic abnormality was found.10 Our case shows relatively 
typical clinical features of PTC and FVPTC, with two episodes 
of LN metastasis, newly developed lesion of FVPTC, and bone 
metastasis during the 15 years of follow-up.
In the present case, the tumor showed BRAF expression in 
areas that are histologically different from FVPTC. These fea-
tures suggested that the newly developed FVPTC and the pre-
existing tumor were essentially different tumors. Furthermore, 
although the features of the LN metastasis and BRAF expres-
sion were compatible with conventional PTC, the histologic 
features were not. Therefore, the diagnosis of WDT-UMP is 
thought to be inadequate, and we suggested the diagnosis of 
EWD-PTC, stressing histologic features different from conven-
tional PTC and excluding the possibility of underdiagnosis at 
the same time.
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